Corporate presentation

DBV, a revolution in immunotherapy

News

DBV Technologies Announces ToplineResults of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

Events

Documentation

20F- Form 2016

Video : The Epicutaneous Immunotherapy Company

Investor Relations

Phone : +33 1 55 42 78 78
Fax : +33 1 43 26 10 83